Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Operating expenses:
Research and development	$ 27,488	$ 17,598	$ 54,917	$ 29,843
In-process research and development		5,488	2,000	9,168
General and administrative	8,417	5,098	15,493	8,780
Total operating expenses	35,905	28,184	72,410	47,791
Loss from operations	(35,905)	(28,184)	(72,410)	(47,791)
Other income (expense)
Interest income	388	31	502	61
Other expense	(91)	(61)	(158)	(116)
Change in fair value of preferred stock purchase right liability				1,615
Total other income (expense), net	297	(30)	344	1,560
Net loss	$ (35,608)	$ (28,214)	$ (72,066)	$ (46,231)
Net loss per share, basic	$ (0.30)	$ (1.20)	$ (0.60)	$ (2.02)
Net loss per share, diluted	$ (0.30)	$ (1.20)	$ (0.60)	$ (2.02)
Weighted-average shares of common stock used in computing net loss per share, basic	120,193,973	23,546,390	119,844,633	22,893,533
Weighted-average shares of common stock used in computing net loss per share, diluted	120,193,973	23,546,390	119,844,633	22,893,533
Other comprehensive income (loss):
Unrealized loss on marketable securities, net	$ (272)	$ (2)	$ (1,061)	$ (3)
Comprehensive loss	$ (35,880)	$ (28,216)	$ (73,127)	$ (46,234)